Larimar Therapeutics, Inc. (LRMR) Financial Statements
Larimar Therapeutics, Inc. (LRMR) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$172.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$156.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LRMRLarimar Therapeutics, Inc.Follow LRMR — free
—
Price chart with a free account
- Market cap
- 244.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 27.4 | 54.6 | 39.9 | 40.8 | 47.9 | 20.8 | 31.4 | 38.4 | 24.3 | 27.7 | 73.3 | 154.2 | 157.3 | |
| Operating income | -35.5 | -73.8 | -58.2 | -53.0 | -61.1 | -23.2 | -42.8 | -50.5 | -36.5 | -41.8 | -90.9 | -172.5 | -179.0 | |
| Pre-tax income | -36.5 | -74.3 | -57.9 | -52.0 | -61.4 | -23.2 | -42.5 | -50.6 | -35.4 | -36.9 | -80.6 | -165.7 | -172.6 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -36.5 | -74.3 | -57.9 | -52.0 | -61.4 | -23.1 | -42.5 | -50.6 | -35.4 | -36.9 | -80.6 | -165.7 | -172.6 | |
| Diluted EPS ($) | -3.00 | -2.78 | -2.12 | -1.90 | -1.90 | -3.80 | -3.57 | -2.95 | -1.37 | -0.84 | -1.32 | — | — | |
| Diluted shares (mn) | — | — | — | — | — | — | — | 17.2 | 25.8 | 43.9 | 61.3 | — | — |
USD millions · SEC XBRL
Larimar Therapeutics, Inc. — questions
- What is Larimar Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Larimar Therapeutics, Inc.'s net income?
- -$172.6M over the twelve months to 2026-06-30.
- What is Larimar Therapeutics, Inc.'s free cash flow?
- -$156.1M over the twelve months to 2026-06-30.
Every figure on this page comes from Larimar Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.